Litcius/Paper detail

LBA3 Perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) in early-stage non-small-cell lung cancer (NSCLC): A 4-year update of KEYNOTE-671

Margarita Majem, M.C. Garassino, G. Zhao, B. Mennecier, C. Grohe, Namiko Ikeda, J. Bosch-Barrera, Roger Keresztes, Yinjun Lou, H. Chen, Debasis Das, Sandra Keller, Ayman Samkari, Jonathan Spicer, H. Wakelee

2024Immuno-Oncology Technology6 citationsDOIOpen Access PDF

Topics & Concepts

PembrolizumabMedicineOncologyStage (stratigraphy)PerioperativeChemotherapyLung cancerInternal medicineCancerRadiologyImmunotherapyBiologyPaleontologyCancer Immunotherapy and BiomarkersCancer, Stress, Anesthesia, and Immune ResponseLung Cancer Diagnosis and Treatment
LBA3 Perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) in early-stage non-small-cell lung cancer (NSCLC): A 4-year update of KEYNOTE-671 | Litcius